Physician profile
Zhalet Baharestan
NPI 1962489559
$7,949.02
in general payments reported to CMS, 2019-2025
38 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $1,262 · 2021: $1,655 · 2022: $999 · 2023: $1,106 · 2024: $1,046 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.01 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,288.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $880.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $868.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $736.52 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $350.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $325.60 | 2019-2021 | |
| Pfizer INC. | $324.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $311.35 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $266.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Tris Pharma INC | $248.46 | 2023-2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $240.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.69 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Azurity Pharmaceuticals, INC. | $200.90 | 2023-2025 | Edarbi, Edarbi, Horizant |
| Endo Pharmaceuticals INC. | $173.60 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $172.88 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhalet Baharestan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.